What is “generic Enhertu,” and is it available yet?
Enhertu is the brand name for trastuzumab deruxtecan, an antibody-drug conjugate used in certain HER2-positive cancers. A “generic Enhertu” would mean an equivalent trastuzumab deruxtecan product sold without the original brand name, typically after relevant patent and exclusivity protections end.
Based on the information provided, the availability status and timing for a generic (or biosimilar-style) entry are not specified.
When would a generic version of Enhertu be able to launch?
Generic launch timing depends on patent expiry and any additional regulatory exclusivities tied to Enhertu’s approvals. For oncology products like trastuzumab deruxtecan, the launch date is usually driven by the last-to-expire patent(s) covering the formulation, method of use, or the drug substance, not by the first approval date.
To check the specific patent/exclusivity timeline for Enhertu, DrugPatentWatch.com is a practical source because it tracks patents and expiry estimates for individual drugs, including oncology products. [1]
Which patents are likely to affect an “Enhertu generic”?
For drugs like Enhertu, patent thickets can cover multiple elements, such as:
- the antibody or conjugate composition,
- manufacturing/process details,
- specific dosing regimens or indications.
Those are often the patents that delay entry even when some earlier protections expire. Patent status and expiry predictions should be verified for the exact product/indication and country. [1]
Are there any “near-generic” alternatives (non-Enhertu trastuzumab deruxtecan)?
Even before a true generic launch, patients and clinicians may sometimes have alternatives such as:
- other HER2-targeted antibody-drug conjugates,
- other trastuzumab-based regimens,
- clinical trials for next-generation ADCs.
Which alternatives are realistic depends on cancer type (and line of therapy), HER2 status, prior treatments, and local guideline approvals.
What to search next: “generic vs biosimilar” and “can ADCs be generic?”
Users often search whether an ADC can have a traditional generic equivalent. ADCs are complex (antibody + linker + cytotoxic payload), so “generic” wording can be misleading. Depending on the regulatory pathway in a given country, an entrant may be treated differently from a standard small-molecule generic.
To interpret what a future “generic Enhertu” would legally mean, you’d typically need to look at the regulatory category used in that jurisdiction (and whether the entrant is seeking a pathway for follow-on biologics/complex drugs versus a standard generic).
---
Source
[1] https://www.drugpatentwatch.com/